Novelna Inc.
Novelna Inc. is a proteomics-based liquid biopsy startup dedicated to transforming cancer diagnostics through innovative, accurate, and affordable early disease detection technologies. Their mission is to ensure early disease detection is accessible to all, leveraging advanced proteomics and AI-enabled platforms to develop highly sensitive and specific diagnostic tests for cancer and other diseases. With a focus on early detection, Novelna aims to improve health outcomes globally by making diagnostics more accessible, precise, and cost-effective.
Industries
Nr. of Employees
small (1-50)
Products
Proteomic multi-cancer early detection test (sex-specific small-protein panel)
A plasma protein-based diagnostic panel using a sex-specific set of approximately 10 proteins designed to detect multiple early-stage solid tumors with reported high sensitivity and specificity in a proof-of-concept study.
Pipeline of blood- and urine-based diagnostic panels
A portfolio of blood- and urine-based proteomic diagnostic panels at varying stages of development optimized for early-stage disease detection.
Proteomic multi-cancer early detection test (sex-specific small-protein panel)
A plasma protein-based diagnostic panel using a sex-specific set of approximately 10 proteins designed to detect multiple early-stage solid tumors with reported high sensitivity and specificity in a proof-of-concept study.
Pipeline of blood- and urine-based diagnostic panels
A portfolio of blood- and urine-based proteomic diagnostic panels at varying stages of development optimized for early-stage disease detection.
Services
Proteomic biomarker discovery and validation platform (service)
Rapid identification and clinical validation of protein biomarkers using a multi-disease discovery design and independent cohort validation workflows.
Proteomic biomarker discovery and validation platform (service)
Rapid identification and clinical validation of protein biomarkers using a multi-disease discovery design and independent cohort validation workflows.
Expertise Areas
- Proteomics-based biomarker discovery
- Multi-cancer early detection
- Plasma and urine diagnostic panel development
- Machine learning for diagnostic classification
Key Technologies
- Plasma proteomics
- Urine proteomics
- Proximity extension assays
- Machine learning classification models